Literature DB >> 10348759

Use of microdilution panels with and without beta-lactamase inhibitors as a phenotypic test for beta-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens.

K S Thomson1, C C Sanders, E S Moland.   

Abstract

Over the past decade, a number of new beta-lactamases have appeared in clinical isolates of Enterobacteriaceae that, unlike their predecessors, do not confer beta-lactam resistance that is readily detected in routine antibiotic susceptibility tests. Because optimal methodologies are needed to detect these important new beta-lactamases, a study was designed to evaluate the ability of a panel of various beta-lactam antibiotics tested alone and in combination with beta-lactamase inhibitors to discriminate between the production of extended-spectrum beta-lactamases, AmpC beta-lactamases, high levels of K1 beta-lactamase, and other beta-lactamases in 141 isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, and Serratia marcescens possessing well-characterized beta-lactamases. The microdilution panels studied contained aztreonam, cefpodoxime, ceftazidime, cefotaxime, and ceftriaxone, with and without 1, 2, and 4 microg of clavulanate per ml or 8 microg of sulbactam per ml and cefoxitin and cefotetan with and without 8 microg of sulbactam per ml. The results indicated that a minimum panel of five tests would provide maximum separation of extended-spectrum beta-lactamase high AmpC, high K1, and other beta-lactamase production in Enterobacteriaceae. These included cefpodoxime, cefpodoxime plus 4 microg of clavulanate per ml, ceftazidime, ceftriaxone, and ceftriaxone plus 8 microg of sulbactam per ml. Ceftriaxone plus 2 microg of clavulanate per ml could be substituted for cefpodoxime plus 4 microg of clavulanate per ml without altering the accuracy of the tests. This study indicated that tests with key beta-lactam drugs, alone and in combination with beta-lactamase inhibitors, could provide a convenient approach to the detection of a variety of beta-lactamases in members of the family Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348759      PMCID: PMC89285          DOI: 10.1128/AAC.43.6.1393

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  49 in total

1.  Development of "oligotyping" for characterization and molecular epidemiology of TEM beta-lactamases in members of the family Enterobacteriaceae.

Authors:  C Mabilat; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Epidemiology of extended spectrum beta-lactamases.

Authors:  A Philippon; S Ben Redjeb; G Fournier; A Ben Hassen
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

Review 3.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

4.  Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins.

Authors:  C H O'Callaghan; P W Muggleton; G W Ross
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

5.  Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases.

Authors:  G P Katsanis; J Spargo; M J Ferraro; L Sutton; G A Jacoby
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

6.  Incidence of strains producing extended spectrum beta-lactamases in Argentina.

Authors:  J M Casellas; M Goldberg
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

7.  Use of an isogenic Escherichia coli panel to design tests for discrimination of beta-lactamase functional groups of Enterobacteriaceae.

Authors:  A F Ehrhardt; C C Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

8.  Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 beta-lactamase (LAT-2).

Authors:  M Gazouli; L S Tzouvelekis; E Prinarakis; V Miriagou; E Tzelepi
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

9.  Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center.

Authors:  L B Rice; E C Eckstein; J DeVente; D M Shlaes
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

10.  Clinical isolates of Escherichia coli producing TRI beta-lactamases: novel TEM-enzymes conferring resistance to beta-lactamase inhibitors.

Authors:  G Vedel; A Belaaouaj; L Gilly; R Labia; A Philippon; P Névot; G Paul
Journal:  J Antimicrob Chemother       Date:  1992-10       Impact factor: 5.790

View more
  22 in total

1.  Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  C C Sanders; M Peyret; E S Moland; C Shubert; K S Thomson; J M Boeufgras; W E Sanders
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Authors:  Christine C Sanders; Anton F Ehrhardt; Ellen Smith Moland; Kenneth S Thomson; Barbara Zimmer; Darcie E Roe
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

Review 3.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals.

Authors:  Ellen Smith Moland; Jennifer A Black; Jason Ourada; Mark D Reisbig; Nancy D Hanson; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 5.  Recent developments in beta lactamases and extended spectrum beta lactamases.

Authors:  Joumana N Samaha-Kfoury; George F Araj
Journal:  BMJ       Date:  2003-11-22

6.  Extended-spectrum beta-lactamases in Ireland, including a novel enzyme, TEM-102.

Authors:  Dearbháile Morris; Colette O'Hare; Maura Glennon; Majella Maher; Geraldine Corbett-Feeney; Martin Cormican
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

7.  Modification of the double-disk test for detection of enterobacteriaceae producing extended-spectrum and AmpC beta-lactamases.

Authors:  J D D Pitout; M D Reisbig; E C Venter; D L Church; N D Hanson
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

8.  Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates.

Authors:  Teresa Spanu; Maurizio Sanguinetti; Mario Tumbarello; Tiziana D'Inzeo; Barbara Fiori; Brunella Posteraro; Rosaria Santangelo; Roberto Cauda; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

9.  Comparison of Phoenix and VITEK 2 extended-spectrum-beta-lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized beta-lactamases.

Authors:  Kenneth S Thomson; Nancy E Cornish; Seong G Hong; Kim Hemrick; Christian Herdt; Ellen S Moland
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

10.  Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?

Authors:  E S Moland; C C Sanders; K S Thomson
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.